Cargando…
SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer
Neoadjuvant chemotherapy (NACT) represents a standard option for breast cancer. Unfortunately, about 55–80% of breast cancer patients do not have a favorable response to chemotherapy. Highly specific tumor biomarker that can predict the pathological response to neoadjuvant chemotherapy is lacking. S...
Autores principales: | Zhao, Weipeng, Sun, Linlin, Li, Xichuan, Wang, Jun, Zhu, Ye, Jia, Yan, Tong, Zhongsheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076324/ https://www.ncbi.nlm.nih.gov/pubmed/33903614 http://dx.doi.org/10.1038/s41598-021-88258-9 |
Ejemplares similares
-
Ribosome Proteins Represented by RPL27A Mark the Development and Metastasis of Triple-Negative Breast Cancer in Mouse and Human
por: Zhao, Weipeng, et al.
Publicado: (2021) -
Clinical significance and prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients
por: He, Yang, et al.
Publicado: (2023) -
Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer
por: Jia, Yan, et al.
Publicado: (2019) -
Decreasing Eukaryotic Initiation Factor 3C (EIF3C) Suppresses Proliferation and Stimulates Apoptosis in Breast Cancer Cell Lines Through Mammalian Target of Rapamycin (mTOR) Pathway
por: Zhao, Weipeng, et al.
Publicado: (2017) -
Elevated Expression of CAV1 is Associated with Unfavorable Prognosis of Patients with Breast Cancer Who Undergo Surgery and Neoadjuvant Chemotherapy
por: Ye, Jia-Hui, et al.
Publicado: (2020)